Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 19/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 19/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 19/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 0.75 |
| ▸ | HTR1B | P28222 | 2/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.75 |
| ▸ | DRD2 | P14416 | 1/20 | 0.75 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.75 |
| ▸ | DRD4 | P21917 | 1/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.75 |
| ▸ | FPR3 | P25089 | 1/20 | 0.75 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.75 |
| ▸ | HTR1D | P28221 | 1/20 | 0.75 |
| ▸ | HTR2A | P28223 | 1/20 | 0.75 |
| ▸ | HTR2C | P28335 | 1/20 | 0.75 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.75 |
| ▸ | GPR183 | P32249 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4809062 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3HTR1AHTR1B | |
| SCHEMBL29798824 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3HTR1AHTR1B | |
| SCHEMBL4801591 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3HTR1AHTR1B | |
| SCHEMBL5074536 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1ADRB3HTR1AHTR1B | |
| SCHEMBL31396315 | 0.98 | ADRB2 (0.97) | ADRB2ADRB1ADRB3HTR1AHTR1B | |
| SCHEMBL939642 | 0.98 | ADRB2 (0.97) | ADRB2ADRB1ADRB3HTR1AHTR1B | |
| SCHEMBL4804563 | 0.93 | ADRB2 (0.87) | ADRB2ADRB1ADRB3HTR1AHTR1B | |
| SCHEMBL4806897 | 0.93 | ADRB2 (0.87) | ADRB2ADRB1ADRB3HTR1AHTR1B | |
| SCHEMBL4806888 | 0.93 | ADRB2 (0.87) | ADRB2ADRB1ADRB3HTR1AHTR1B | |
| SCHEMBL4804551 | 0.93 | ADRB2 (0.87) | ADRB2ADRB1ADRB3HTR1AHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 469 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| EP-2152341-B2 | ATOMIZER IN THE FORM OF AN INHALER FOR MEDICAL AEROSOL THERAPY | BOEHRINGER INGELHEIM PHARMA (DE) | 2025-04-02 | — | — | EP | disclosed |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2025-01-28 | — | — | US | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-04-09 | — | — | US | disclosed |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2024-04-04 | — | — | US | disclosed |
| CN-112279808-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-112250627-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| EP-4223294-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20070107722-A1 | NEEDLE FOR PIERCING A POWDER CAPSULE FOR INHALATION | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-17 | — | — | US | disclosed |
| WO-2007051536-A1 | METHOD AND DEVICE FOR METERING MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG (DE) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007048764-A2 | PROPELLANT FOR DOSING AEROSOLS COMPRISING PACKAGINGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007048763-A1 | INHALER WITH MOUTHPIECE HAVING A MICROBIOLOGICAL PROTECTIVE FUNCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007045670-A1 | OPTICAL SEMI-QUANTITATIVE 100 % FILLING CHECK OF PHARMACEUTICAL CAPSULES ON CAPSULE FILLING MACHINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007023167-A1 | TRANSCORNEAL SYSTEM FOR DELIVERY OF A PHARMACEUTICAL AGENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-01 | — | — | WO | disclosed |
| WO-2006117314-A2 | NOVEL PIPERIDIN- SUBSTITUTED INDOLES AND THEIR USE AS CCR-3 MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-09 | — | — | WO | disclosed |
| US-20060247230-A1 | Novel Piperidine-Substituted Indoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-02 | — | — | US | disclosed |
| US-20060106013-A1 | PI3-kinases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-18 | — | — | US | disclosed |
| WO-2006040279-A1 | PI3 KINASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | ADRB2 55/4885ADRB1 90/4885ADRB3 89/4885 |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | ADRB2 522/4885ADRB1 308/4885ADRB3 421/4885 |
| US-20060106013-A1 | PI3-kinases | PIK3C3, PIK3CB, PIK3CD | ADRB2 2330/4885ADRB1 2017/4885ADRB3 1504/4885 |
| US-20060247230-A1 | Novel Piperidine-Substituted Indoles | CCR3, CCR1, CCR2 | ADRB2 66/4885ADRB1 33/4885ADRB3 21/4885 |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | ADRB2 55/4885ADRB1 90/4885ADRB3 89/4885 |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | ADRB2 522/4885ADRB1 308/4885ADRB3 421/4885 |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | CFTR, SLC26A4, PKD1 | ADRB2 1836/4885ADRB1 1307/4885ADRB3 1299/4885 |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | ADRB2 55/4885ADRB1 90/4885ADRB3 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.